Cargando…

Targeting the CD47-SIRPα Innate Immune Checkpoint to Potentiate Antibody Therapy in Cancer by Neutrophils

SIMPLE SUMMARY: Immunotherapy aims to engage various immune cells in the elimination of cancer cells. Neutrophils are the most abundant leukocytes in the circulation and have unique mechanisms by which they can kill cancer cells opsonized by antibodies. However, neutrophil effector functions are lim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Behrens, Leonie M., van den Berg, Timo K., van Egmond, Marjolein
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9319280/ https://www.ncbi.nlm.nih.gov/pubmed/35884427 http://dx.doi.org/10.3390/cancers14143366

Ejemplares similares

Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα–CD47 innate immune checkpoint
por: Voets, Erik, et al.
Publicado: (2019)

CD47-SIRPα Checkpoint Inhibition Enhances Neutrophil-Mediated Killing of Dinutuximab-Opsonized Neuroblastoma Cells
por: Martínez-Sanz, Paula, et al.
Publicado: (2021)

Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis
por: Hu, Jinyang, et al.
Publicado: (2020)

CD47/SIRPα axis: bridging innate and adaptive immunity
por: van Duijn, Anneloes, et al.
Publicado: (2022)

The SIRPα–CD47 immune checkpoint in NK cells
por: Deuse, Tobias, et al.
Publicado: (2021)

The TSP1-CD47-SIRPα interactome: an immune triangle for the checkpoint era
por: Montero, Enrique, et al.
Publicado: (2023)

Sodium stibogluconate and CD47-SIRPα blockade overcome resistance of anti-CD20–opsonized B cells to neutrophil killing
por: van Rees, Dieke J., et al.
Publicado: (2022)

Role of CD47-SIRPα Checkpoint in Nanomedicine-Based Anti-Cancer Treatment
por: Liao, Haiqin, et al.
Publicado: (2022)

Cancer Therapy Targeting CD47/SIRPα
por: Dizman, Nazli, et al.
Publicado: (2021)

Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and target for cancer immunotherapy
por: Logtenberg, Meike E. W., et al.
Publicado: (2019)

Potential New Cancer Immunotherapy: Anti-CD47-SIRPα Antibodies
por: Lu, Quansheng, et al.
Publicado: (2020)

CD47-SIRPα Checkpoint Disruption in Metastases Requires Tumor-Targeting Antibody for Molecular and Engineered Macrophage Therapies
por: Andrechak, Jason C., et al.
Publicado: (2022)

CD47–SIRPα-targeted therapeutics: status and prospects
por: Maute, R., et al.
Publicado: (2022)

Membrane-Mediated Cooperative Interactions of CD47 and SIRPα
por: Li, Long, et al.
Publicado: (2023)

Expression of CD47 and SIRPα Macrophage Immune-Checkpoint Pathway in Non-Small-Cell Lung Cancer
por: Giatromanolaki, Alexandra, et al.
Publicado: (2022)

CD47/SIRPα pathway mediates cancer immune escape and immunotherapy
por: Jia, Xiao, et al.
Publicado: (2021)

Insights into CD47/SIRPα axis-targeting tumor immunotherapy
por: Zhang, Xuyao, et al.
Publicado: (2018)

CD47‐SIRPα blocking‐based immunotherapy: Current and prospective therapeutic strategies
por: Bouwstra, Renée, et al.
Publicado: (2022)

Bispecific antibody approach for EGFR-directed blockade of the CD47-SIRPα “don’t eat me” immune checkpoint promotes neutrophil-mediated trogoptosis and enhances antigen cross-presentation
por: Hendriks, Mark A. J. M., et al.
Publicado: (2020)

Binding Mechanism of CD47 with SIRPα Variants and Its Antibody: Elucidated by Molecular Dynamics Simulations
por: Huang, Kaisheng, et al.
Publicado: (2023)

Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis
por: Zhang, Wenting, et al.
Publicado: (2020)

Cancer cells under immune attack acquire CD47-mediated adaptive immune resistance independent of the myeloid CD47-SIRPα axis
por: Hendriks, Mark A.J.M., et al.
Publicado: (2021)

Macrophage checkpoint blockade: results from initial clinical trials, binding analyses, and CD47-SIRPα structure–function
por: Jalil, AbdelAziz R, et al.
Publicado: (2020)

Liposome-Based Co-Immunotherapy with TLR Agonist and CD47-SIRPα Checkpoint Blockade for Efficient Treatment of Colon Cancer
por: Chang, Rui, et al.
Publicado: (2023)

A role for CD47 in the development of experimental colitis mediated by SIRPα(+)CD103(−) dendritic cells
por: Fortin, Genevieve, et al.
Publicado: (2009)

Blocking CD47-SIRPα Signal Axis as Promising Immunotherapy in Ovarian Cancer
por: Luo, Xukai, et al.
Publicado: (2023)

Targeting CD47-SIRPα axis for Hodgkin and non-Hodgkin lymphoma immunotherapy
por: Zhao, Pengcheng, et al.
Publicado: (2023)

Is CD47 an innate immune checkpoint for tumor evasion?
por: Liu, Xiaojuan, et al.
Publicado: (2017)

SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells
por: Tahk, Siret, et al.
Publicado: (2021)

Promising alternatives of CD47 monoclonal antibody: an injectable degradable hydrogel loaded with PQ912 for postoperative immunotherapy effectively blocks CD47-SIRPα signal
por: Li, Chang, et al.
Publicado: (2022)

Microglia are effector cells of CD47-SIRPα antiphagocytic axis disruption against glioblastoma
por: Hutter, Gregor, et al.
Publicado: (2019)

CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy
por: Wang, Hongfei, et al.
Publicado: (2020)

Augmentation of CD47/SIRPα signaling protects cones in genetic models of retinal degeneration
por: Wang, Sean K., et al.
Publicado: (2021)

Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy
por: Chen, Huanpeng, et al.
Publicado: (2022)

Targeting the CD47-SIRPα Axis: Present Therapies and the Future for Cutaneous T-cell Lymphoma
por: Xiao, Amy, et al.
Publicado: (2022)

RRx-001 Acts as a Dual Small Molecule Checkpoint Inhibitor by Downregulating CD47 on Cancer Cells and SIRP-α on Monocytes/Macrophages
por: Cabrales, Pedro
Publicado: (2019)

Blocking the CD47-SIRPα interaction reverses the disease phenotype in a polycythemia vera mouse model
por: Lysenko, Veronika, et al.
Publicado: (2023)

Novel CD47: SIRPα Dependent Mechanism for the Activation of STAT3 in Antigen-Presenting Cell
por: Toledano, Natan, et al.
Publicado: (2013)

Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy
por: Zhang, Jin, et al.
Publicado: (2018)

Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors
por: Miller, Thomas W., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8l4ao4jp0lg5v9shv8l9p4qd4b